Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Idexx Laboratories (IDXX)

Idexx Laboratories (IDXX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,657,112
  • Shares Outstanding, K 85,055
  • Annual Sales, $ 2,407 M
  • Annual Income, $ 427,720 K
  • 60-Month Beta 0.85
  • Price/Sales 13.79
  • Price/Cash Flow 64.91
  • Price/Book 121.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 1.39
  • Number of Estimates 4
  • High Estimate 1.48
  • Low Estimate 1.34
  • Prior Year 1.24
  • Growth Rate Est. (year over year) +12.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
329.69 +18.23%
on 07/14/20
407.86 -4.43%
on 07/31/20
+50.31 (+14.82%)
since 07/06/20
3-Month
280.53 +38.94%
on 05/14/20
407.86 -4.43%
on 07/31/20
+106.19 (+37.44%)
since 05/06/20
52-Week
168.65 +131.12%
on 03/23/20
407.86 -4.43%
on 07/31/20
+119.40 (+44.16%)
since 08/06/19

Most Recent Stories

More News
After Yesterday's Decline of 2.43%, Idexx Labs Offers Investors Better Value

Idexx Labs (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $384.19 to a high of $395.74. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $385.22...

IDXX : 389.78 (-1.50%)
IDEXX Laboratories Announces Second Quarter Results

, /PRNewswire/ --

IDXX : 389.78 (-1.50%)
Idexx (IDXX) Soars to 52-Week High, Time to Cash Out?

Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

IDXX : 389.78 (-1.50%)
CERN : 69.95 (+0.92%)
FMS : 43.30 (+0.84%)
RMD : 175.52 (-13.52%)
IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise

IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.

PKI : 119.05 (-2.49%)
TMO : 415.73 (-0.99%)
WST : 273.89 (-0.28%)
IDXX : 389.78 (-1.50%)
Has IDEXX Laboratories (IDXX) Outpaced Other Medical Stocks This Year?

Is (IDXX) Outperforming Other Medical Stocks This Year?

IDXX : 389.78 (-1.50%)
Idexx Laboratories (IDXX) Beats Q2 Earnings and Revenue Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 43.33% and 9.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

IDXX : 389.78 (-1.50%)
Idexx: 2Q Earnings Snapshot

WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $148.9 million.

IDXX : 389.78 (-1.50%)
Will Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?

Amid the pandemic situation, GW Pharmaceuticals (GWPH), which controls its own manufacture and supply chain, is expected to have faced minimum supply-related disruption unlike others.

IART : 47.81 (-0.08%)
IDXX : 389.78 (-1.50%)
EXAS : 90.40 (-1.68%)
GWPH : 132.10 (-2.10%)
Illumina (ILMN) to Report Q2 Earnings: What's in the Offing?

Illumina (ILMN) is upbeat about its second-quarter sequencing consumable revenue growth.

ILMN : 399.33 (-0.35%)
LMNX : 33.12 (-18.22%)
IART : 47.81 (-0.08%)
IDXX : 389.78 (-1.50%)
Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?

IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

IDXX : 389.78 (-1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade IDXX with:

Business Summary

IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff...

See More

Key Turning Points

2nd Resistance Point 401.45
1st Resistance Point 395.62
Last Price 389.78
1st Support Level 384.07
2nd Support Level 378.35

See More

52-Week High 407.86
Last Price 389.78
Fibonacci 61.8% 316.48
Fibonacci 50% 288.26
Fibonacci 38.2% 260.03
52-Week Low 168.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar